Global Idiopathic Pulmonary Fibrosis (IPF) Pipeline Analysis 2016-2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Global Idiopathic Pulmonary Fibrosis (IPF) Pipeline Analysis, 2016" report to their offering.

The IPF pipeline is very strong with a total of 97 drug candidates. Pharma giant such as Asahi Kasei Corporation, Merck & Co., Inc., Biogen and Sanofi are involved in the development of the IPF therapeutics. The IPF pipeline comprised of 97 product candidates, of which one is in Phase III stage, 15 are in Phase II stage, 12 are in Phase I stage, 39 are in Pre-clinical stage, and seven are in discovery stage.

SM04646 is under Phase I stage of development by Samumed, LLC for the treatment of IPF. The drug candidate is a small molecule that acts as Wnt pathway modulator. Samumed is using the technology for development of small molecule that modulate Wnt pathway. The technology is not a stem cell therapy, instead focusing on the modulation of the Wnt pathway that recovers and restores the health of diseased tissues and presents significant opportunities in regenerative therapeutics.

Several companies are involved in IPF with their products in different phases. The only Phase III IPF drug candidate is being developed by Asahi Kasei Pharma Corporation. The IPF pipeline drug candidates of Merck & Co., Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG and FibroGen, Inc. are in Phase II stage of development. Bristol-Myers Squibb Company is also having its IPF pipeline drug candidates in different clinical stages, including two drugs in Phase II and one drug in Phase I.

Some of the key players developing drug candidates for the treatment of IPF are Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Global Blood Therapeutics, Inc., Asahi Kasei Corporation, Beijing Tide Pharmaceutical Co., Limited, FibroGen, Inc., Chong Kun Dang Pharmaceutical Corp., Galapagos NV, Kadmon Holdings, Inc., MediciNova, Inc., and Promedior, Inc.

Key Topics Covered:

1. Research Scope And Methodology

2. Executive Summary

3. Pipeline Outlook

4. Global Idiopathic Pulmonary Fibrosis (Ipf) Pipeline Analysis By Phase (2016)

5. Swot Analysis Of Idiopathic Pulmonary Fibrosis Pipeline

6. Company Profiles And Strategic Developments

7. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/998z58/global_idiopathic

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Respiratory Drugs, Respiratory Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Respiratory Drugs, Respiratory Drugs